The mechanism by which 2'-deoxyguanosine is toxic for lymphoid cells is relevant both to the severe cellular immune defect of inherited purine nucleoside phosphorylase (PNP) deficiency and to attempts to exploit PNP inhibitors therapeutically. We have studied the cell cycle and biochemical effects of 2'-deoxyguanosine in human lymphoblasts using the PNP inhibitor 8-aminoguanosine. We show that cytostatic 2'-deoxyguanosine concentrations cause Gj-phase arrest in PNP-inhibited T lymphoblasts, regardless of their hypoxanthine guanine phosphoribosyltransferase status. This effect is identical to that produced by 2'-deoxyadenosine in adenosine deaminase-inhibited T cells. 2'-Deoxyguanosine elevates both the 2'-deoxyguanosine-5'-triphosphate (dGTP) and 2'-deoxyadenosine-5'-triphosphate (dATP) pools; subsequently pyrimidine deoxyribonucleotide pools are depleted. The time course of these biochemical changes indicates that the onset of GI-phase arrest is related to increase of the dATP rather than the dGTP pool. When dGTP elevation is dissociated from dATP elevation by coincubation with 2'-deoxycytidine, dGTP does not by itself interrupt transit from the GI to the S phase.
Introduction
Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP,' EC 2.4.2.1) is associated with severely impaired cellular immune function (1) (2) (3) . In contrast, the more common adenosine deaminase (ADA, EC 3.5.4.4) deficiency causes a combined immune deficiency with marked reduction in both humoral and cellular immunity (4, 5) . PNP mediates the catabolism ofthe purine nucleosides guanosine and inosine, and their corresponding deoxynucleosides to the parent bases guanine and hypoxanthine. These bases may then either be salvaged by hypoxanthine guanine phosphoribosyltransferase (HGPRTase) to ribonucleotides or further catabolized to uric acid. All four PNP precursors have been shown to be present at high levels in the urine of PNP-deficient individuals, with elevation of plasma inosine and guanosine and mild hypouricemia (3) .
Purine deoxyribonucleosides have long been known to be toxic to lymphoid cells, particularly to those of thymic origin (6) . Several mechanisms of 2'-deoxyadenosine toxicity have been proposed and investigated, using ADA inhibitors, such as erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and deoxycoformycin, which allow biochemical modeling of ADA deficiency (7, 8) . Clinical trials of deoxycoformycin as an antilymphoid agent in leukemia and lymphoma have also been reported (9, 10) .
The demonstration of elevated levels of dATP in the erythrocytes of ADA-deficient individuals focussed attention on this deoxynucleotide as a mediator of 2'-deoxyadenosine lymphotoxicity (1 1) . This is attractive because T cells have a greater capacity than B cells to elevate their 2'-deoxyadenosine-5'-triphosphate (dATP) levels, providing an explanation for their greater sensitivity to 2'-deoxyadenosine (7, (12) (13) (14) .
It has long been proposed that the basic mechanism of dATP toxicity in proliferating cells is by inhibiting ribonucleotide reductase (E.C. 1.17.4.1), thus depriving DNA synthesis of substrates such as 2'-cytosine-5'-triphosphate (dCTP)-the "ribonucleotide reductase hypothesis." This has been supported by studies of mutant murine and human T cells with reduced sensitivity to 2'-deoxyadenosine and dATP-resistant ribonucleotide reductase (15). However, doubt has been cast on this interpretation by the lack of a consistent relationship between deoxyribonucleotide triphosphate (dNTP) pool changes, primary inhibition of DNA synthesis and end points such as growth inhibition or cell death (6) . Further, a study of the differential incorporation of thymidine and uridine into DNA, although supporting a primary inhibition of DNA synthesis, was not consistent with ribonucleotide reductase inhibition (16) . Finally, neither the arrest in the GI phase of the cell cycle by dividing T lymphoblasts nor the cytotoxicity for resting lymphocytes ofmicromolar 2'-deoxyadenosine concentrations (in the presence of ADA inhibitor) are explained by current models of inhibition ofribonucleotide reductase (17, 18) . Alternative modes oftoxicity have been proposed and documented such as inhibition of methylation reactions, ATP depletion, and interference with RNA synthesis (6) . Though NAD depletion has now been convincingly associated with 2'-deoxyadenosine-induced cell death in resting lymphocytes (19) , at this stage it appears no single mechanism explains all observations in dividing cells.
Earlier studies had also demonstrated the lymphotoxicity of 2'-deoxyguanosine, attention focussing on 2'-deoxyguanosine-5'-triphosphate (dGTP) as a toxic metabolite by virtue of both its capacity to inhibit CDP reduction (and therefore DNA synthesis) and its selective accumulation in T cells (20) (21) (22) (23) . Elevated dGTP levels were subsequently reported in erythrocytes from a PNP-deficient patient (24). 2'-Deoxyguanosine-resistant mutant mouse lymphoblasts with PNP deficiency and altered ribonucleotide reductase have also been described (25, 26) . Nucleoside incorporation studies have confirmed that DNA synthesis can be inhibited by micromolar concentrations of2'-deoxyguanosine in the absence of a PNP inhibitor, and have shown that incorporation of uridine into DNA is suppressed more than that of thymidine, consistent with inhibition of ribonucleotide reductase (16) .
The recent availability ofa reasonably potent PNP inhibitor, 8-aminoguanosine (K;, 17 AM), has allowed a more refined approach to the pathophysiology ofthis PNP deficiency and to the evaluation of PNP inhibition as a possible cytotoxic strategy (27) . At micromolar concentrations of 2'-deoxyguanosine in the presence of PNP inhibitor, dGTP pool elevation has been documented in T lymphoblasts and mitogen-stimulated lymphocytes, and has been correlated with inhibition of proliferation (28) . In contrast, GTP has been shown to be the major toxic metabolite for B lymphoblasts and mature T cell lines (29) .
We have examined the effect of 2'-deoxyguanosine on the cell cycle kinetics of PNP-inhibited human T lymphoblasts by flow cytometric techniques. We have correlated these effects with changes in nucleotide pools, comparing and contrasting them with the analogous effects of 2'-deoxyadenosine. We show that, in the presence of a PNP inhibitor, 2'-deoxyguanosine, as well as causing an elevation of the dGTP pool, induces a secondary but delayed rise in the dATP pool, apparently via allosteric effects on ribonucleotide reductase. This secondary dATP rise is associated with the development ofG1 phase arrest, a phenomenon independent of inhibition of ribonucleotide reductase per se. ,ul of ethidium bromide (400 ;g/ml in 1% Triton X-100) and 300 ;l of mithramycin (125 ug/ml in 1% Triton X-100, 75 mM MgCI2) to 10'6 cells in 2 ml ofcomplete medium. Samples ofthe stained cells were then excited at 360-460 nm and the resulting fluorescence was measured at wavelengths below 550 nm (30) .
Methods
For the 5-bromodeoxyuridine labeling experiment, DNA staining with Hoechst 33342 was performed as previously described (30, 31) . Briefly, 106 cells in 2 ml of complete medium were permeabilized by addition of 1.5 vol ofice-cold 0.1% Triton X-100 containing 0.1 M HCI and 0.15 M NaCl. After 2 min the cells were centrifuged and the pellet was resuspended in 0.1 M Tris-HCI buffer, pH 7.4, containing Hoechst 33342 (1 Mg/ml). Samples of stained cells were then excited at 360 nm and the resulting fluorescence measured at 450 nm (450± 10 nm bandpass filter).
Approximately 30,000 cells were analyzed for each DNA content histogram. Unfixed chicken erythrocytes (105) were added to each sample before staining as an internal standard to allow for any variation in machine performance and staining procedures. Calculations ofpercentages ofcells in various phases ofthe cell cycle were made using a curve-fitting method of analysis (32) . Typically, aliquots taken simultaneously from the same culture and separately stained for DNA content as described above yielded values for cell-cycle phase percentages that varied from the mean by standard deviations of less than 1%. Nucleotide (dNTP and NTP) analysis. Aliquots of 5-10 X 10' cells were spun and washed once in Dulbecco's phosphate-buffered saline (in g/100 ml: NaC 0.8, KC 0.02, Na2HPO4 0.115, KH2PO4 0.02) containing EDTA 2 mM, extracted in ice-cold 60% ethanol and stored at -20°C. After lyophilization, cell extracts were taken up in 500 Ml of 10 mM Tris buffer, pH 7.85, and spun at 40,000 g at 4°C for 10 min and the supernatants were stored at -20°C. dNTP pools were measured by a modification ofthe DNA polymerase assay (17, 33, 34 Ribonucleotide triphosphates (NTPs) were quantified by high-performance liquid chromatography as described (29) . NTPs and dNTPs were eluted from a Partisil-1O SAX anion exchange column (Whatman Laboratory Products, Inc., Clifton, NJ) using a linear ammonium phosphate gradient (0.30-0.45 M, pH 3.3-3.6 over 35 min) at a flow rate of 2 ml/min. Nucleotides were detected and identified by their absorbances at 254 and 280 nm and compared with calibration curves of nanomole amounts of pure standards.
Results
Growth inhibition of lymphoblasts by 2-deoxyguanosine. The effect of 2'-deoxyguanosine and coincubation with 8-aminoguanosine on the growth of wild-type and HGPRTase-deficient T lymphoblasts is shown in Table I . Concentrations of up to 500 AM 8-aminoguanosine were studied and, though it did not inhibit growth by itself, 8-aminoguanosine potentiated the toxicity of 2'-deoxyguanosine in a concentration-dependent fashion. 50 ,M 8-aminoguanosine caused more than a fourfold reduction in the ID50 (48 h) of 2'-deoxyguanosine with no significant further potentiation at higher concentrations. Further experimentation focussed on conditions that caused "cytostasis," by which we mean maximal inhibition of growth without significant reduction of cell numbers from initial control values. In the T lymphoblasts studied, this criterion was met at 20 AM 2'-deoxyguanosine in the absence of8-aminoguanosine and at 5 MM 2'-deoxyguanosine in its presence, though small (<5%) percentages of nonviable cells could be detected at slightly lower concentrations of 2'-deoxyguanosine. Conditions that did lead to net cell killing have been designated "cytocidal."
The EBV-transformed B lymphoblasts studied (Table I) had somewhat lower sensitivities to 2'-deoxyguanosine than T cells. 2'-Deoxyguanosine toxicity was not enhanced by 50 AM 8-aminoguanosine and, as recently reported (29) Analytical DNA flow cytometric analysis of2-deoxyguanosine growth inhibition. A cytostatic concentration of 2'-deoxyguanosine (20 AM) alone produced a cell cycle-nonspecific block in wild-type T lymphoblasts ( Fig. 1 B) , whereas HGPRTasedeficient T lymphoblasts were predominantly blocked in the GI phase of the cell cycle ( Fig. 1 C) . Though unexpected, this blockade was similar to that induced by 2'-deoxyadenosine in ADA-inhibited T lymphoblasts (17) . This indicated that the specific GI-phase arrest seen in HGPRTase-deficient T cells was due to residual 2'-deoxyguanosine, its deoxyribonucleotides, or direct products of its hydrolysis by PNP and not to guanine salvage. We therefore proceeded to examine the effect of PNP inhibition on 2'-deoxyguanosine toxicity in wild-type T lymphoblasts.
In the presence of the PNP inhibitor 8-aminoguanosine, a cytostatic concentration of 2'-deoxyguanosine (5 MM) caused a specific G,-phase arrest, leading to a maximum of 80-90% GI cells by 18 h (Fig. 1, D 2) confirmed this interpretation, as was the case in the GI block caused by cytostatic concentrations of 2'-deoxyadenosine in ADA-inhibited T lymphoblasts (31).
DNA that has incorporated 5-bromouracil instead ofthymine binds the fluorochrome combination ethidium bromide/mithramycin normally but does not bind Hoechst 33342, whereas normal DNA binds both stains quantitatively. Hoechst 33342 DNA microfluorimetry of cultures incubated in 5-bromodeoxyuridine alone thus shows progressive diminution ofthe original GI peak as cells, having been exposed to 5-bromodeoxyuridine for increasing periods of time during S phase, return to form a second, less fluorescent GI peak (Fig. 2 B) . CCRF-CEM T lymphoblasts were incubated in the presence of 5 AM (Fig. 1 F) .
All these observations were replicated in further human T Effect of 2-deoxyguanosine on nucleotide pools. 8-aminoguanosine did not by itselfsignificantly alter dNTP or GTP levels. In PNP-inhibited T lymphoblasts 5 MM 2'-deoxyguanosine perturbed all four dNTP pools, with prompt elevation ofboth dGTP and dATP and subsequent delayed depletion of dCTP and to a lesser extent dTTP (Fig. 3) . This pattern was consistent with stimulation by dGTP of ADP reduction and inhibition of CDP and UDP reduction according to the standard model of allosteric regulation of ribonucleotide reductase (34-36).
Inasmuch as the same cell-cycle perturbation, GI-phase arrest, can be produced by either 2'-deoxyadenosine or 2'-deoxyguanosine in T lymphoblasts, it is therefore significant that dATP elevation is common to both situations. In 2'-deoxyadenosinetreated cells it is the only early dNTP abnormality (17) , whereas in cells treated with 2'-deoxyguanosine, dATP elevation is associated with but preceded by dGTP elevation. Because it seemed that the cause of the GI-phase arrest would be most evident in the biochemical changes pertaining at the time ofits onset (rather than hours or days later), the time courses of the various dNTP changes were compared more closely.
ADA-inhibited CCRF-CEM T lymphoblasts exposed to 3
,uM 2'-deoxyadenosine began to accumulate excess cells in GI from 2 h (Fig. 4 A) , by which time the dATP pool had increased by 1.5-fold (Fig. 4 B) . dATP continued to rise rapidly whereas the other dNTPs were unchanged until 8 h had elapsed, as has previously been described (17) . By 24 h dGTP had fallen to 20% of control whereas dCTP and dTTP had increased by 1.5-and threefold, respectively (data not shown), but no further cell-cycle disturbances were noted. At the time of onset of GI-phase arrest the only abnormality was an expansion of the dATP pool of about 1.5-fold.
In PNP-inhibited CCRF-CEM lymphoblasts exposed to 5 AM 2'-deoxyguanosine, the percentage of cells in GI phase did not rise until after 3 h of incubation (Fig. 4 A) . By this time both the dGTP and dATP pools had increased but, whereas the dGTP pool had exceeded control levels by 1.8-fold by 1 h and 3.5-fold by 3 h, the dATP pool rose more gradually, reaching 1.5 times control at about 3 h (Fig. 4 B) . By 24 h dGTP was 30 times and dATP eight times control (Fig. 3) . Thus although 2'-deoxyguanosine induced a dGTP elevation steeper than the analogous dATP rise induced by 2'-deoxyadenosine, GI-phase arrest in 2'-deoxyguanosine-treated cells was delayed until a dATP increase of about 1.5 times control occurred. This dATP increase was similar to that seen in the 2'-deoxyadenosine-treated cells at the time GI-phase arrest became apparent. The dCTP pool did not fall significantly until 8 h had elapsed, but fell to 20% of control by 24 h, whereas the dTTP pool was only reduced after 16 h of incubation ( Fig. 3) . At 24 h GTP levels were not significantly increased (Table II) and ATP levels were unchanged in four experiments. When PNP-inhibited CCRF-CEM lymphoblasts were incubated at a higher 2'-deoxyguanosine concentration (20 AM) dGTP elevation was more rapid, exceeding 20 times control after 6 h. dCTP depletion was similarly rapid and profound (20% of control at 6 h) and dATP elevation was similar to that produced by 5 AM 2'-deoxyguanosine (data not shown). GTP levels doubled over 24 h (Table II) tivity of T lymphoblasts to 2'-deoxyguanosine is associated with the capacity of the T phenotype for accumulation of deoxyribonucleotides. B lymphoblasts (JP), as previously reported (29) , failed to elevate their dGTP or dATP pools significantly. Effectofcoincubation with2-deoxycytidine. 2'-Deoxycytidine wholly or partially prevents the cytotoxic effects of 2'-deoxyadenosine/ADA inhibitor combinations on T lymphoblasts, apparently by competing with 2'-deoxyadenosine for phosphorylation (17) . At low concentrations of 2'-deoxyguanosine (10 ALM or less) in the presence of 8-aminoguanosine, 2'-deoxycytidine protected T lymphoblasts from growth inhibition in a concentration-dependent manner, such that normal growth was maintained by 10 uM 2'-deoxycytidine. At higher 2'-deoxyguanosine concentrations (up to 40 ,M was tested) protection was partial, but cell counts did not fall provided at least 3 uM 2'-deoxycytidine was present (Fig. 5) .
At 5 MM 2'-deoxyguanosine in the presence of 8-aminoguanosine, coincubation with 2'-deoxycytidine prevented GI-phase arrest (Fig. 6,4 and B). After 24 h the dGTP pool had doubled and the dCTP and dTTP pools were respectively 1.3 and 1.7 times control values, but dATP had not increased (Table III) .
GTP levels were unchanged (Table II) while ATP levels fell by 16% in two experiments.
At 20 MM 2'-deoxyguanosine in the presence of 8-aminoguanosine, coincubation with 2'-deoxycytidine prevented cell death; however growth was not restored (Fig. 5) and DNA microfluorimetry at 24 h showed this was due to a block in S phase of the cell cycle (Fig. 6, C and D) . By this time the dGTP pool was 10 times control, dATP and dCTP had fallen to 20% and 80% of control, respectively, and the dTTP pool had increased 1.9-fold (Table III) . GTP was elevated over sixfold (Table II) and ATP was reduced to 46% of control in two experiments. Despite these multiple biochemical abnormalities including pronounced dGTP elevation, it is noteworthy that transit from the GI to the S phase was completely unimpaired. This especially argues against there being a dGTP-sensitive "target" capable of causing GI arrest independently of dATP. Effect of2-deoxyguanosine on peripheral blood lymphocytes.
ADA-inhibited PBL are exquisitely sensitive to 2'-deoxyadenosine-only 20% survive 96 h of incubation in 1 MM 2'-deoxyadenosine, having accumulated dATP (18) . In contrast, PBL were only killed by 2'-deoxyguanosine concentrations of at least 100 ,M, the presence or absence of 50 MM 8-aminoguanosine having little effect (Fig. 7) . After 24 h at 300 uM 2'-deoxyguanosine, the dGTP pool in PNP-inhibited cells was elevated to over 10 times control, but no dATP rise was detected. The latter was not surprising, given the fact that recorded activities of ribonucleotide reductase in PBL are very low (37) , and gives indirect support to the notion that 2'-deoxyguanosine elevates the dATP pool in proliferating lymphoid cells by stimulation ofADP reduction.
Discussion
We have shown that, at cytostatic concentrations of 2'-deoxyguanosine, PNP-inhibited T lymphoblasts committed to DNA synthesis complete that cycle and proceed through G2 and mitosis, whereas cells already in GI or returning there are arrested.
T lymphoblasts incubated at cytostatic concentrations of 2'-deoxyadenosine and an ADA inhibitor differ only in that they manifest an earlier onset of GI-phase arrest. Comparing the respective elevations of dGTP and dATP in these experiments, it is apparent that the time of onset ofthe G1 block correlates best with expansion of the dATP pool rather than with the other dNTP pool perturbations. Further, when 2'-deoxycytidine protects these cells from GI-phase arrest dATP is not elevated but dGTP is. Higher, cell-killing 2'-deoxyguano~ine concentrations cause mixed cell cycle and biochemical effects. Secondary dATP pool elevation has previously been described in 2'-deoxyguanosine-treated human and murine lymphoblasts (16, 21) , mitogen-stimulated human lymphocytes (34), and S-phase ("large") human thymocytes (37), but has not drawn comment as a direct mediator of 2'-deoxyguanosine toxicity. It almost certainly occurs by allosteric stimulation of ADP reduction by dGTP; this effect has been demonstrated in ribonucleotide reductase preparations, including that isolated from a human lymphoblastoid line (38) .
However, a proposal that dATP is the common mediator by which both 2'-deoxyadenosine and 2'-deoxyguanosine cause GI-phase arrest must take into account other known modes of 2'-deoxyguanosine toxicity. These are chiefly the ribonucleotide reductase (dNTP depletion) hypothesis and guanine ribonucleotide accumulation and will be dealt with in turn. dCTP is depleted at cytostatic 2'-deoxyguanosine concentrations but this is quite delayed and may reflect the normal low dNTP pools of GI cells as much as inhibition of CDP reductase by dGTP. The ribonucleotide reductase hypothesis would predict interruption of ongoing DNA synthesis by dCTP depletion, but we have shown that cells already in S phase complete DNA synthesis unimpeded. Specific inhibitors of ribonucleotide reductase such as hydroxyurea cause an S-phase block at cytostatic concentrations (17) . In further contrast the G -phase arrest induced by 2'-deoxyadenosine is associated with a static or slightly elevated dCTP pool. The evidence is thus against a role for dCTP depletion in 2'-deoxyguanosine-induced GI-phase arrest.
Catabolism of 2'-deoxyguanosine and salvage to guanine ribonucleotides is an important cause of its toxicity to B lymphoblasts and mature T cell lines, but not for HGPRTase-deficient B cell lines or PNP-inhibited T lymphoblasts (29, 39) . In our experiments with T lymphoblasts GTP was not increased by 2'- deoxyguanosine concentrations that caused GI-phase arrest, and we have found that HGPRTase-deficient T lymphoblasts similarly block in GI. At higher concentrations of 2'-deoxyguanosine GTP elevation occurred indicating some escape from the competitive inhibition of PNP by 8-aminoguanosine, an effect described by others (29, 39, 40) . This would have contributed to the nonselective cell-cycle changes, such as delay in S or G2/M, and the cell killing seen under these conditions. The mechanisms of guanine ribonucleotide toxicity are not fully clear as a wide variety of cellular functions may be involved, but they have been shown to include inhibition of de novo purine synthesis (41) ; this may account for the reduction in ATP caused by high 2'-deoxyguanosine concentrations in our experiments. As is shown by the cell cycle changes in B cells reported by ourselves and others (41) , DNA synthesis may also-be affected by guanine ribonucleotide accumulation.
Finally, it may be proposed that in 2'-deoxyguanosine-treatdd T lymphoblasts an as yet unidentified effect of dGTP causes the GI arrest despite the concurrent dATP increase. Dissociation of dGTP elevation from dATP elevation is difficult in principle given that the latter is caused by the former, but we feel the 2'-deoxycytidine "rescue" experiments do so and make such a role for dGTP unlikely.
As in 2'-deoxyadenosine toxicity, coincubation with 2'-deoxycytidine can wholly prevent 2'-deoxyguanosine toxicity (6, 17) . A major mechanism in protection from 2'-deoxyadenMechanism ofDeoxyguanosine Toxicity 1267 20001 1000 Ao osine toxicity is competition for phosphorylation by a common deoxyribonucleoside kinase, thus limiting or preventing dATP accumulation. Similar competition with 2'-deoxyguanosine has been proposed because 2'-deoxyguanosine, 2'-deoxyadenosine and 2'-deoxycytidine kinase activity may be represented by a single-protein species (6, 7, 21) . At the lower, cytostatic 2'-deoxyguanosine concentration normal growth was restored and GI arrest prevented by 2'-deoxycytidine despite a persistently (albeit less) elevated dGTP. This argues against direct toxicity ofdGTP elevation per se. More conclusive is the observation that at 20 gM 2'-deoxyguanosine, in the presence of 2'-deoxycytidine, a 10-fold elevation of dGTP did not hinder transit from the GI to the S phase in the absence of dATP elevation (which was suppressed by adenine pool depletion).
In summary, of the diverse biochemical changes caused by incubating T lymphoblasts in 2'-deoxyguanosine and PNP inhibitor, only dATP elevation is consistently associated with G1-phase arrest. Potential mechanisms by which dATP could produce a specific GI-phase arrest may be considered as either related or unrelated to ribonucleotide reductase. Examples ofthe latter include the evidence that 2'-deoxyadenosine/ADA inhibitor combinations can interfere with RNA synthesis, as shown by inhibition of transcription in both peripheral blood lymphocytes and CCRF-CEM cells (42) . Also, dAMP residues have been shown to be incorporated from dATP into the terminal position of poly(A)+ messenger RNA, possibly affecting its subsequent processing (43) . Interference by dATP in the synthesis or consumption ofother adenine nucleotides such as NAD, poly (ADPribose) and diadenosine 5',5Iw-P',P4-tetraphosphate (Ap4A) may occur (19) . These compounds have been shown to be associated with the regulation ofcell cycle transitions including the initiation and cessation of DNA synthesis. Their deoxy analogues-2'-dNAD, poly (dADP-ribose), and dideoxyadenosine 5',5m-P'P4-tetraphosphate-have been synthesized in vitro but not yet detected in vivo (44, 45) .
Despite these possibilities the characteristics of cultured T cell lines (murine and human) with mutation at the dATP binding site on the Ml subunit of ribonucleotide reductase must be taken into account ( 15, 46) . These cell lines are resistant to growth inhibition by 2'-deoxyadenosine, implying that ribonucleotide reductase is the target for dATP-mediated toxicity, albeit not by the classical model of inhibition in T cells. A possible interpretation ofthe effects ofdeoxynucleosides in vitro (at least in whole cells) is that the effects of 2'-deoxyguanosine (and thymidine) on the dNTP pools of T cells are in accord with existing models of the allosteric control of ribonucleotide reductase. However, the effect of 2'-deoxyadenosine on dNTP pools is not in accord with these models; that is, dCTP pools do not fall after the rise in dATP and a GI-phase arrest occurs. This suggests that in intact cells the interaction of dATP with the allosteric subunit may differ from that in purified enzyme preparations. The subunit behavior of ribonucleotide reductase is now quite involved and a putative "replitase" complex has been described. Comprising DNA polymerase, topoisomerase, thymidylate synthetase, ribonucleotide reductase, and other enzymes concerned with DNA replication, it is proposed to form from the individual enzyme components at the end of GI and to serve to appropriately channel metabolites for DNA replication (47, 48) . Ribonucleotide reductase allosteric (M,) and catalytic (M2) subunits also appear to be assembled together at the G, /S interface. Because the state ofaggregation ofMl in vitro can be readily altered by dATP, polymers being formed in its presence (49), we postulate that 2'-deoxyadenosine and 2'-deoxyguanosine toxicity in replicating T cells could be mediated by the binding of dATP to the allosteric subunit of ribonucleotide reductase. This does not necessarily inhibit the catalytic (M2) subunit but rather, via conformational change and possibly formation ofMl polymers, interferes with assembly of "replitase" at the GI /S interface and results in GI-phase arrest.
As in 2'-deoxyadenosine toxicity, the cell cycle effect of cytostatic 2'-deoxyguanosine concentrations is quite specific. Previous reports of 2'-deoxyguanosine toxicity in proliferating lymphoid cells have for the most part described the effects of high concentrations which have multiple cell-cycle and biochemical effects. Though 8-aminoguanosine does not ideally model absolute PNP deficiency, its use has allowed investigation of the lymphotoxicity of 2'-deoxyguanosine concentrations likely to be encountered in PNP-deficient or inhibited individuals. As a result a final common pathway for 2'-deoxyguanosine and 2'-deoxyadenosine toxicity is apparent, namely an as yet unidentified dATP-sensitive target crucial to progression into the DNA synthetic phase of the cell cycle.
